Assessment of health economics in Alzheimer's disease (AHEAD): Galantamine treatment in Canada

Neurology

Volumn 57, Issue 6, 2001, Pages 972-978

  Getsios, D ^a   Caro, J Jaime ^b,c   Caro, G ^a   Ishak, K ^a  

^a Caro Research Institute   (Canada)

^b CARO RESEARCH INSTITUTE   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE;

ALZHEIMER DISEASE; ARTICLE; CANADA; CHRONIC DISEASE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; NURSING HOME; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035949734     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.6.972     Document Type: Article

References (29)

1. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia
2. Canadian study of health and aging: Study methods prevalence of dementia
3. Net economic costs of dementia in Canada
4. Relation between disease severity and costs of caring
5. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
6. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multi-centre, randomized controlled trial
7. A 5-month, randomized, placebo-controlled trial of galantamine in AD
8. A new rating scale for Alzheimer's disease
9. Galantamine: Additional benefits to patients with Alzheimer's disease
10. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care
11. Recommendations of the Panel on Cost-effectiveness in Health and Medicine
12. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician
13. Predicting time to nursing home care and death in individuals with Alzheimer disease
14. Modified Mini-Mental State Examination: Validity and reliability
15. The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials
16. Health utilities in Alzheimer's disease. A cross-sectional study of patients and caregivers
17. The Global Deterioration Scale for the assessment of primary degenerative dementia
18. Modelling mini mental state examination changes in Alzheimer's disease
19. Assessing the societal impact of acetylcholinesterase inhibitor therapies
20. Drug treatments for Alzheimer's disease: Shifting the burden of care
21. Galantamine: Therapeutic effects beyond cognition
22. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease
23. The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer's disease
24. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease
25. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
26. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine